Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.36 |
| ▸ | MME | P08473 | 4/20 | 0.35 |
| ▸ | CPA1 | P15085 | 3/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.35 |
| ▸ | ECE1 | P42892 | 4/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP7 | P09237 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28515194 | 0.88 | ACE (0.36) | ACEMMECPA1ACE2ECE1 | |
| SCHEMBL25355936 | 0.87 | ACE (0.36) | ACEMMECPA1ACE2ECE1 | |
| SCHEMBL8896490 | 0.87 | ACE (0.41) | ACEMMECPA1ACE2ECE1 | |
| SCHEMBL30781182 | 0.86 | ACE (0.35) | ACEMMECPA1ACE2ECE1 | |
| SCHEMBL18921925 | 0.86 | ACE (0.35) | ACEMMECPA1ACE2ECE1 | |
| SCHEMBL29071842 | 0.85 | ACE (0.38) | ACEMMECPA1ACE2ECE1 | |
| SCHEMBL30035137 | 0.85 | CTRB1 (0.34) | ACEMMECPA1ACE2 | |
| SCHEMBL3916119 | 0.84 | CTRB1 (0.37) | ACEMMECPA1ACE2 | |
| SCHEMBL17293240 | 0.84 | CTRB1 (0.37) | ACEMMECPA1ACE2 | |
| SCHEMBL749822 | 0.84 | CTRB1 (0.37) | ACEMMECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150770-A1 | METHODS OF TREATING SKIN | TRACIE MARTYN INTERNATIONAL INC (US) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150770-A1 | METHODS OF TREATING SKIN | CUTA, LIPA, DLAT | ACE 2659/4885MME 2696/4885CPA1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.